Manipal Health IPO Opens: Key Numbers and Broker Ratings

Manipal Health Enterprises’ ₹9,275 crore initial public offering opens for subscription on July 29 and closes on July 31, with a price band of ₹560–590 per share. At the upper end, retail investors need ₹14,750 for a minimum lot of 25 shares. Grey market cues suggest a listing premium of around 2.3%, with shares trading at roughly ₹603.5 in the unofficial market.

The issue consists of a fresh equity issue of ₹8,000 crore and an offer for sale of 2.16 crore shares. Post-listing, the promoters’ stake will drop from 69.87% to 61.84%, and the company is expected to command a market capitalisation of about ₹77,607 crore.

Brokerages have offered mixed recommendations. SBI Securities rates the IPO a ‘Subscribe’, citing Manipal’s leadership in key metro markets, its acquisition-driven expansion and a planned 2,426-bed addition by FY30, along with margin improvement from debt reduction. Angel One and Arihant Capital, however, hold a ‘Neutral’ view, concerned about rich pricing—Angel One highlights a post-issue FY26 P/E of 84.6x, leaving little room for near-term gains. Emkay Global did not assign a rating but noted a discount to sector EV/EBITDA multiples.

The bulk of the fresh proceeds—₹5,552.7 crore—will repay loans taken for the Sahyadri Hospitals acquisition, cutting the company’s total ₹11,185 crore debt by nearly 47.5%. Another ₹574 crore is earmarked to buy out the remaining 9.84% stake in Sahyadri. Shares are expected to list on August 5.

Why Analysts Are Divided on the Issue

Debt Overhang from Sahyadri Acquisition

Manipal Health’s aggressive buyout strategy has pushed total debt to ₹11,185 crore as of March 2026. The Sahyadri deal, financed largely through borrowings, is the main target of the IPO proceeds. Repaying over half the debt would lower interest costs significantly and could lift return on capital employed, which Emkay Global flagged as lagging peers. A cleaner balance sheet may also support future expansion, but near-term earnings remain burdened by the interest outgo until the IPO funds flow in.

Valuation: Priced for Perfection or Fairly Valued?

The post-issue FY26 P/E of 84.6x is a sticking point. Angel One argues this leaves limited upside, while SBI Securities points to a 29.4x EV/EBITDA—close to the sector average—as reasonable. Emkay’s internal estimate of 30x EV/pre-Ind AS EBITDA appears to echo that relative fairness. However, both the high P/E and the modest grey market premium of ₹13.5 (implying a 2.3% listing gain) signal that the market isn’t expecting a sharp re-rating soon. Investors are effectively asked to pay for the company’s long-term growth story upfront.

Market Leadership in Three Metros

Manipal Health is the only private hospital chain with the top market share in Bengaluru, Kolkata, and Pune simultaneously. With 49 hospitals and 13,037 licensed beds, it has unmatched scale. The planned addition of 2,426 beds by FY30—if executed well—could widen this moat. Yet the premium valuation already reflects this dominant position, so any disappointment in bed additions or margin improvement could hurt the stock.

What the Grey Market Premium Actually Says

A GMP of ₹13.5 over an issue price of ₹590 translates to a likely listing at ₹603.5, a gain of just 2.3%. For an IPO where retail investors often chase double-digit listing pops, this is subdued. It suggests institutional interest may be lukewarm, possibly due to the large issue size and rich pricing. For those looking for a quick flip, the risk-reward is unfavourable. Long-term holders, however, may view the listing price as a low-stress entry if they believe in the management’s debt-reduction plan and growth story.

Should You Subscribe? A Practical Framework for Retail Investors

  • Check your risk appetite. At 84.6x FY26 P/E, the stock is not cheap. A near-term correction cannot be ruled out if the market re-rates hospital stocks or if the company’s margin improvement is slower than expected. Only apply if you are comfortable with volatility and a holding period of at least two to three years.
  • Look beyond listing gains. The grey market premium points to a meagre 2.3% listing pop. If you are investing solely for a quick profit, the numbers don’t support a strong case. Treat this as a long-term bet on India’s healthcare demand and Manipal’s expansion story.
  • Track debt reduction closely. The IPO’s success hinges on slashing nearly half the ₹11,185 crore debt. Watch the next quarterly results for evidence that lower interest costs are translating into higher margins and improved return ratios. That will be the real validation of the “Subscribe” thesis.
  • Use the price band to your advantage. Bidding at the upper end (₹590) means you are paying the most for the story. If you are sceptical about near-term upside, consider applying at the cut-off price near the lower band (₹560) to build in a margin of safety, though the grey market suggests the upper band is still the likely final price.